Frontlight ResearchEarly access
Duchenne muscular dystrophy trials in Hong Kong
1 trial · From ClinicalTrials.gov, checked 15 November 2026. Ask the study team whether a trial fits you.
- Phase 3Enrolling by invitationA Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study
- Where
- Hong Kong
- Age
- Up to 64 years
- People
- 400 worldwide
- Run by
- Sarepta Therapeutics, Inc.
See details and how to joinNCT05967351 · EU 2023-505043-39-00